RxDoctor Payments DataLook up a doctor →

Tyler Webb, MD

Neurology · Oklahoma City, OKNPI 1770718108

Payments from drug & device makers

$23,223in general payments, 2019–2025

Across 1,141 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$9K
  • AbbVie$4K
  • Novartis$947
  • Pfizer$935
  • Supernus Pharmaceuticals, Inc.$867
  • Sanofi$543
  • plus $7K from 52 others

What the payments were for

  • Consulting fees$3,25014%
  • Speaking & faculty fees$3,80916%
  • Travel & lodging$8774%
  • Food & beverage$15,24266%
  • Education$440%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.58$8,860
AbbVie(2 entities)374$3,918
Novartis84$947
Pfizer73$935
Supernus Pharmaceuticals, Inc.61$867
Sanofi28$543
Biogen23$478
Lundbeck LLC18$374
Sunovion Pharmaceuticals Inc.32$373
Argenx US, Inc.18$360
Teva Pharmaceuticals USA, Inc.36$349
Acadia Pharmaceuticals Inc22$328
Bristol Myers Squibb21$325
AstraZeneca18$303
MDD US Operations, LLC17$294
SK Life Science, Inc.13$279
Upsher-smith Laboratories LLC32$276
E.r. Squibb & Sons, L.L.C.20$250
Merz Pharmaceuticals, LLC8$224
Biohaven Pharmaceuticals, Inc.22$211
Amgen10$208
Biohaven Pharmaceutical Holding Company Ltd.16$190
Genentech USA, Inc.10$188
Sumitomo Pharma America, Inc.21$188
CSL Behring9$184
Vanda Pharmaceuticals Inc.4$153
Livanova USA, Inc.5$140
Lilly USA, LLC8$132
Neurocrine Biosciences, Inc.8$128
TG Therapeutics, Inc.7$123
Eisai Inc.5$104
EMD Serono, Inc.6$101
Amneal Pharmaceuticals LLC7$93
Alnylam Pharmaceuticals Inc.5$75
Acorda Therapeutics, Inc4$59
ANI Pharmaceuticals, Inc.3$57
Grifols USA, LLC3$57
Arbor Pharmaceuticals, Inc.4$54
GE HealthCare2$46
Mallinckrodt Enterprises LLC2$41
Strongbridge US Inc.3$40
Promius Pharma LLC2$33
Jazz Pharmaceuticals Inc.2$33
Xeris Pharmaceuticals, Inc.2$32
Zogenix Inc.2$27
Takeda Pharmaceuticals U.S.A., Inc.1$25
Banner Life Sciences, LLC1$23
Ultragenyx Pharmaceutical Inc.1$23
Avion Pharmaceuticals1$23
Impel Pharmaceuticals LLC1$22
Merz North America, Inc.1$20
Tanabe Pharma America, Inc.1$19
Medtronic1$19
Azurity Pharmaceuticals, Inc.1$18
Catalyst Pharmaceuticals, Inc.1$16
Corium, LLC1$14
Adamas Pharmaceuticals, Inc.1$12
Johnson & Johnson1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,223 in reported general payments places this provider in the 75th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$333,712
Medicare patients
644
Services billed
29,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5026$292,539
Gamunex-CImmune Globul G/Gly/Iga Avg 4643$185,457
BriviactBrivaracetam41$69,305
Emgality PenGalcanezumab-Gnlm51$43,734
RytaryCarbidopa/Levodopa23$34,879
Aimovig AutoinjectorErenumab-Aooe26$34,393
UbrelvyUbrogepant21$34,361
QuliptaAtogepant14$21,723
Lacosamide120$6,280
Memantine Hcl128$5,409
Levetiracetam107$3,740
Mycophenolate Mofetil42$3,190
Gabapentin101$2,653
Propranolol Hcl ErPropranolol Hcl51$2,434
Candesartan Cilexetil19$2,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$184$292,53926 claims
Grifols USA, LLCGamunex-C$57$185,45743 claims
UCB, Inc.Briviact$8,860$69,30541 claims
AbbVieUbrelvy, Qulipta$3,918$56,08535 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$93$39,61885 claims
Upsher-smith Laboratories LLCTopiramate$276$1,09690 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 neurology providers in Oklahoma.

Other neurology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →